Is Allopurinol Bad for Your Kidneys?

Allopurinol does not damage healthy kidneys, and it is one of the most commonly prescribed medications for people who already have kidney disease. In large clinical trials, allopurinol has not been shown to worsen kidney function compared to a placebo. The more nuanced reality is that it also hasn’t proven to protect kidneys the way researchers once hoped, and in rare cases, a serious allergic reaction to the drug can cause acute kidney injury. Understanding those layers matters if you take allopurinol or are considering it.

Why Allopurinol Gets Prescribed Alongside Kidney Disease

Allopurinol works by blocking an enzyme called xanthine oxidase, which is responsible for the final steps of uric acid production in the body. By shutting down that enzyme, allopurinol dramatically lowers the amount of uric acid circulating in your blood and filtering through your kidneys. That makes it the go-to drug for gout, where uric acid crystals deposit in joints, but it’s also widely used in people with kidney problems because high uric acid levels and kidney disease tend to travel together.

The connection between uric acid and the kidneys goes beyond gout. Elevated uric acid activates the immune system and pushes kidney cells toward inflammation and scarring, affecting the tubes that filter waste, the blood vessels that supply the kidney, and the tissue in between.¹ That’s why researchers spent years testing whether lowering uric acid with allopurinol could slow kidney disease. The logic was straightforward: if uric acid damages kidneys, reducing it should help. The evidence, however, turned out to be more complicated.

What the Largest Trial Actually Found

The study that reshaped clinical thinking on this question is a trial called CKD-FIX, published in the New England Journal of Medicine. It enrolled patients with chronic kidney disease who were at high risk of getting worse and randomly assigned them to either allopurinol or a placebo. After following these patients, the researchers found that kidney function declined at virtually the same rate in both groups. The allopurinol group lost about 3.3 mL per minute per year in kidney filtration rate, and the placebo group lost about 3.2 mL per minute per year. The difference was statistically meaningless.²

That result was disappointing, because earlier, smaller studies had pointed in the opposite direction. A 2010 trial followed patients with stage 3 kidney disease for two years and found that the group taking allopurinol actually gained a small amount of kidney function, while the control group lost function over the same period. Allopurinol also appeared to reduce cardiovascular events in that study.³ A more recent systematic review pooling four trials with about 700 participants reported that allopurinol significantly improved kidney filtration compared to control groups.⁴

So why the conflicting results? The smaller trials had fewer participants, shorter follow-up, and less rigorous designs. When the larger, more carefully controlled CKD-FIX trial came along, the earlier promise faded. The current consensus among kidney specialists is that allopurinol does not slow chronic kidney disease progression and should not be prescribed for that purpose alone. It remains appropriate for gout management and for preventing uric acid kidney stones, but the kidney-protective dream has not panned out in the strongest available evidence.

When Allopurinol Can Directly Harm the Kidneys

While routine use of allopurinol doesn’t erode kidney function, there is a rare but serious way the drug can hurt kidneys: through a severe allergic reaction. The most feared version is called DRESS syndrome, short for drug reaction with eosinophilia and systemic symptoms. It involves fever, widespread rash, and organ damage that can hit the kidneys, liver, or both.

In one reported case, a 71-year-old man who had recently started allopurinol developed fever, a diffuse rash, and rapidly worsening kidney function. A kidney biopsy revealed severe inflammation packed with immune cells, confirming that the drug had triggered an intense allergic reaction inside the kidney tissue itself.⁵ This kind of reaction can progress to permanent kidney damage or even require dialysis if it isn’t caught and treated quickly. Stopping the drug and using steroids to calm the immune response are the usual steps.

An even more dangerous variant involves Stevens-Johnson syndrome or toxic epidermal necrolysis, conditions where the skin blisters and peels off in sheets. These are life-threatening, and allopurinol is one of the more commonly implicated drugs. The kidney involvement in these cases ranges from mild inflammation to full-blown organ failure, depending on how far the reaction progresses before treatment.

Genetic Screening Can Predict Who’s at Risk

The good news about allopurinol hypersensitivity is that we know the main genetic culprit. A gene variant called HLA-B*5801 dramatically increases the risk of severe skin reactions. A systematic review and meta-analysis found that carriers of this variant had roughly 80- to 97-fold higher odds of developing Stevens-Johnson syndrome or toxic epidermal necrolysis from allopurinol, depending on the study design used.⁶ A study in Han Chinese patients in Hong Kong found that every patient who had a severe skin reaction to allopurinol carried HLA-B*5801, while only about 13% of those who tolerated the drug had the variant. Sensitivity for predicting a severe reaction was 100%, and specificity was nearly 87%.⁷

The frequency of HLA-B*5801 varies by ethnicity. It’s carried by roughly 6 to 8% of people with Southeast Asian or African ancestry, around 3 to 4% of Korean and Han Chinese populations, and less than 2% of people with European ancestry. Current guidelines from the American College of Rheumatology recommend testing for HLA-B*5801 before starting allopurinol, especially in populations where the variant is more common. If you carry it, you should not take allopurinol. The screening test is a simple blood draw and can prevent a potentially fatal reaction.

People with reduced kidney function are at extra risk even beyond genetics, because the kidneys clear allopurinol’s active breakdown product more slowly. That means the drug and its metabolite linger at higher concentrations, which may increase the likelihood and severity of a hypersensitivity reaction. This is why doctors typically start at low doses in patients with kidney disease and raise the dose gradually.

How Febuxostat Compares for Kidney Outcomes

Febuxostat is the other major xanthine oxidase inhibitor, and a natural question for anyone with kidney concerns is whether it’s gentler on the kidneys than allopurinol. The answer, frustratingly, depends on which study you read and how you weight the evidence.

A network meta-analysis of patients with stage 3 to 5 kidney disease found that febuxostat was associated with a roughly 5 mL/min improvement in filtration rate compared to allopurinol, though the confidence interval crossed zero, meaning it could have been a chance finding.⁸ One long-term comparison reported that the kidney filtration trend was positive in the febuxostat group and negative in the allopurinol group.⁹ An earlier systematic review found that febuxostat lowered albuminuria (a marker of kidney damage) more than allopurinol, but the actual filtration rate difference between the two drugs disappeared by three months.¹⁰

A large head-to-head trial where at least a third of participants had stage 3 kidney disease found that allopurinol was noninferior to febuxostat for controlling gout flares, and the outcomes were similar in the kidney disease subgroup.¹¹ Meanwhile, a study of a related drug (febuxostat) in patients with kidney disease and no proteinuria found that it slowed kidney decline in that specific subgroup, even though it didn’t help the overall study population.¹²

The practical takeaway is that febuxostat may have a slight edge in certain kidney disease subgroups, but the differences are small and inconsistent across studies. Neither drug has proven itself as a true kidney protector in the way that, say, certain blood pressure medications have.

The Cardiovascular Wrinkle

Choosing between allopurinol and febuxostat isn’t just about kidneys. A large U.S. trial called CARES enrolled gout patients who already had cardiovascular disease and compared the two drugs. The overall rate of cardiovascular events was similar, but febuxostat was linked to higher rates of death from heart-related causes and death from any cause. The risk of cardiovascular death was about 34% higher with febuxostat, and all-cause mortality was about 22% higher.¹³ That result triggered an FDA boxed warning on febuxostat and made allopurinol the clear first-line choice for most patients.

The story didn’t end there. A European trial called FAST, which was larger, had better follow-up, and enrolled patients who more closely reflected typical gout patients, reached a different conclusion. In that study, febuxostat was noninferior to allopurinol for cardiovascular events, and there was no excess mortality. If anything, numerically fewer patients died in the febuxostat group.¹⁴ The CARES trial had a dropout rate above 50%, which may have skewed its mortality findings. Still, the FDA warning remains in place, and most guidelines continue to recommend starting with allopurinol unless there’s a good reason not to.¹⁵

Dosing Allopurinol When Kidneys Are Already Impaired

For decades, doctors reflexively capped allopurinol doses in patients with reduced kidney function. The concern was that the active metabolite, oxypurinol, is cleared by the kidneys, so it accumulates when kidneys aren’t working well. Higher oxypurinol levels were thought to increase the risk of hypersensitivity reactions. This led to dose ceilings as low as 100 mg per day for patients with moderately impaired kidney function, which often meant the drug couldn’t get uric acid levels low enough to actually control gout.

Modern guidelines have moved away from those rigid caps. The current approach is to start low (often 100 mg daily or even 50 mg in advanced kidney disease) and gradually increase the dose every few weeks while monitoring uric acid levels, aiming for a target below 6 mg/dL. This “start low, go slow” strategy lets doctors find the right dose for each patient rather than imposing a blanket restriction that leaves many people undertreated. The key safety measure isn’t dose limitation but rather HLA-B*5801 screening before the first pill and careful monitoring during dose escalation.

Allopurinol itself is rapidly converted in the body to oxypurinol, which does most of the long-term enzyme blocking. The parent drug binds the enzyme much more tightly than oxypurinol does — roughly ten-fold higher affinity — but oxypurinol persists in the body much longer, so it ends up doing the heavy lifting.¹⁶ In patients with poor kidney function, oxypurinol’s extended half-life is both what makes the drug effective at lower doses and what demands careful titration.

Why Many Patients Stop Taking It

One of the more underappreciated problems with allopurinol isn’t the drug’s effect on the body but the body’s effect on the drug’s use. Adherence to allopurinol is notoriously poor. A national cohort study of U.S. veterans found that patients with kidney disease, heart disease, and several other chronic conditions were actually less likely to stick with their allopurinol prescriptions than healthier patients.¹⁷ The irony is that these are the patients who tend to have the highest uric acid levels and the most to gain from treatment.

Part of the problem is that allopurinol doesn’t make you feel better immediately. In fact, when you first start it, uric acid levels drop rapidly, which can paradoxically trigger gout flares. That early worsening discourages many people from continuing. Doctors typically prescribe an anti-inflammatory alongside allopurinol for the first several months to prevent these flares, but if the purpose of the drug and the timeline aren’t clearly communicated, patients understandably lose faith in a pill that seems to make things worse before it makes them better.

What Allopurinol Costs Compared to Febuxostat

For patients weighing their options, cost is a real factor. Allopurinol is a generic drug that has been available for decades and is inexpensive. Febuxostat, while now also available in generic form in some countries, remains more costly. A systematic review of cost-effectiveness studies found that febuxostat typically costs over $1,200 more per patient than allopurinol over a treatment course, though the incremental cost per quality-adjusted life year remained below commonly used thresholds in most analyses.¹⁸ Given that the kidney and gout-control outcomes between the two drugs are broadly similar in head-to-head trials, allopurinol’s affordability is a major reason it remains the default first choice worldwide.

For people with kidney disease who cannot tolerate allopurinol due to HLA-B*5801 positivity or a prior hypersensitivity reaction, febuxostat becomes the standard alternative despite the lingering cardiovascular questions from the CARES trial. In that situation, the kidney data favoring febuxostat in certain subgroups can actually be reassuring, even if the overall evidence for kidney protection from either drug is thin.